Cocrystal Pharma Profile

USD 0.04  0.91%

Exercise or conversion by Raymond Schinazi of 263158 shares of Cocrystal Pharma subject to Rule 16b-3

Cocrystal Pharma insider trading alert for exercise of 8% convertible note by Raymond Schinazi, the corporate stakeholder, on May 14, 2018. This event was filed by Cocrystal Pharma Inc with SEC on 2018-05-14. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

Cocrystal Pharma Summary

Cocrystal Pharma (COCP) is traded on BATS Exchange in USA. It is located in GEORGIA U.S.A and employs 10 people. Cocrystal Pharma is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Small-Cap' category with current market capitalization of 115.5 M. Cocrystal Pharma conducts business under Healthcare sector and is part of Pharmaceutical Products industry. This company has 29.92 M outstanding shares of which 45.34 K shares are currently shorted by private and institutional investors with about 0.29 trading days to cover. COCRYSTAL PHARMA currently holds about 1.25 M in cash with (6.93 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.05.
Check Cocrystal Pharma Probability Of Bankruptcy

Ownership Allocation (%)

Target Price Odds Analysis

Odds Below 4.34HorizonTargetOdds Above 4.34
87.19%30 days 4.34 12.74%
Based on normal probability distribution, the odds of Cocrystal Pharma to move above current price in 30 days from now is about 12.74% (This Cocrystal Pharma probability density function shows the probability of Cocrystal Pharma Stock to fall within a particular range of prices over 30 days) .

Cocrystal Pharma Risk Profiles

Key Fundamentals

Cocrystal Pharma Against Markets

Current Ratings

Cocrystal Pharma 30 Days Performance Scores
Risk Adjusted
Performance Score (0 to 100)
Chance of
Financial Distress (0 to 100%)
Equity ratings for Cocrystal Pharma are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Cocrystal Pharma, Inc., a clinical stage biotechnology company, engages in discovering and developing various novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses. Cocrystal Pharma, Inc. was founded in 2007 and is headquartered in Tucker, Georgia. Cocrystal Pharma operates under Biotechnology classification in USA and traded on OTC Market. It employs 10 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Cocrystal Pharma SEC Filings
Cocrystal Pharma SEC Filings
Security & Exchange Commission EDGAR ReportsView All
NameCocrystal Pharma
CEO and DirectorJeffrey MecklerView All
Macroaxis Advice
Healthcare, Biotechnology
InstrumentUSA Stock View All
Business Address1860 Montreal Road
ExchangeBATS Exchange
IndustryPharmaceutical Products
Phone678 892 8800
CurrencyUSD - US Dollar

Current Sentiment - COCP

Cocrystal Pharma Investor Sentiment
Macroaxis portfolio users are unresponsive in their opinion about investing in Cocrystal Pharma. What is your opinion about investing in Cocrystal Pharma? Are you bullish or bearish?
50% Bullish
50% Bearish

Cocrystal Pharma Corporate Directors

Raymond Schinazi Director, CFA
Steven Rubin Director
Phillip Frost Director
Check also Trending Equities. Please also try Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.